Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer

Japanese Journal of Clinical Oncology

Volumn 43, Issue 8, 2013, Pages 827-834

  Miyazaki, Jun ^a   Hinotsu, Shiro ^b,c   Ishizuka, Naoki ^d   Naito, Seiji ^c,e   Ozono, Seiichiro ^c,f   Akaza, Hideyuki ^c,g   Nishiyama, Hiroyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c BCG Connaught Study Group   (Japan)

^d Sanofi KK   (Japan)

^e KYUSHU UNIVERSITY HOSPITAL   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adverse reactions; Bacillus Calmette gu rin; Maintenance therapy; Non muscle invasive bladder cancer

Indexed keywords

BCG VACCINE;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BLADDER DISEASE; BLADDER TAMPONADE; CANCER IMMUNIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTALGIA; DISEASE SEVERITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSURIA; FEMALE; HEMATURIA; HUMAN; HYPERTENSION; LOWER ABDOMINAL PAIN; MAINTENANCE THERAPY; MALAISE; MALE; MEDICATION COMPLIANCE; MICTURITION DISORDER; NON MUSCLE INVASIVE BLADDER CANCER; PATIENT COMPLIANCE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; VACCINATION REACTION;

ADVERSE REACTIONS; BACILLUS CALMETTE-GUÉRIN; MAINTENANCE THERAPY; NON-MUSCLE-INVASIVE BLADDER CANCER;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; BCG VACCINE; CARCINOMA IN SITU; FEMALE; HEMATURIA; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYCOBACTERIUM BOVIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 84881095407     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt086     Document Type: Article

References (20)

1. Herr HW, Laudone VP, Badalament RA, et al. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988;6:1450-5.
2. Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996;156:1934-40. Discussion 40-1.
3. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86-91. Discussion 2.
4. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124-9.
5. Hinotsu S, Akaza H, Naito S, et al. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int 2010;108:187-95.
6. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette- Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
7. Bohle A, Bock PR. Intravesical bacille Calmette -Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-6. Discussion 6-7.
8. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-5.
9. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-14.
10. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-30.
11. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.
12. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette - Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 1991;325:1205-9.
13. van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R. Intravesical instillation of epirubicin, bacillus Calmette- Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial J Urol 2001;166:476-81.
14. Lamm DL, Blumenstein BA, David Crawford E, et al. Randomized intergroup comparison of bacillus Calmette-Guérin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol 1995;1:119-26.
15. Japan, Clinical, Oncology, Group. National Cancer Institute-Common Toxicity Criteria (NCI-CTC) Version 2.0, 2nd Edn. Tokyo, Japan: Japanese Version of Japan Clinical Oncology Group, 2001.
16. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance Bacillus Calmette-Guérin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44:429-34.
17. Saint F, Irani J, Patard JJ, et al. Tolerability of bacille Calmette- Guérin maintenance therapy for superficial bladder cancer. Urology 2001;57:883-8.
18. Koga H, Kuroda M, Kudo S, et al. Adverse drug reactions of intravesical bacillus Calmette-Guérin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder. Int J Urol 2005;12:145-51.
19. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, et al. Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174:1242-7.
20. Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006;176:935-9.